<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02999854</url>
  </required_header>
  <id_info>
    <org_study_id>CR-AIR-009</org_study_id>
    <secondary_id>2016-004672-21</secondary_id>
    <nct_id>NCT02999854</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer</brief_title>
  <acronym>HATCY</acronym>
  <official_title>A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiadis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiadis Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare safety and efficacy of a haploidentical
      T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell
      replete HSCT with post-transplant administration of high dose cyclophosphamide (PTCy) in
      patients with a hematologic malignancy. An additional objective of the study is to compare
      the effect of the two treatments on quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study CR-AIR-009 is a Phase III randomized controlled multicenter open-label study comparing
      two parallel groups. After signing informed consent, a total of 195 patients will be
      randomized in a 1:1 fashion to receive either a T-cell depleted hematopoietic stem cell
      transplantation (HSCT; CD34 selection) from a related, haploidentical donor, followed by
      ATIR101 infusion, or a T-cell replete HSCT, followed by a high dose of post-transplant
      cyclophosphamide (PTCy).

      Randomization will use minimization to balance treatment groups with respect to underlying
      disease (AML, ALL, or MDS), Disease Risk Index (DRI; intermediate risk, high risk, or very
      high risk) and center. A stochastic treatment allocation procedure will be used so that the
      treatment assignment is random for all patients entered in the study.

      Patients randomized in the ATIR101 group will receive a single ATIR101 dose of 2×10E6 viable
      T-cells/kg between 28 and 32 days after the HSCT. Patients randomized in the PTCy group will
      receive cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT. All patients will be
      followed up for 24 months post HSCT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft-versus-host disease-free, relapse-free survival (GRFS)</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
    <description>Time from randomization until grade III/IV acute GVHD, chronic GVHD requiring systemic immunosuppressive treatment, disease relapse, or death, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
    <description>Time from randomization until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
    <description>Time from randomization until relapse, disease progression, or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-related mortality (RRM)</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
    <description>Time from randomization to death due to disease relapse or disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality (TRM)</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
    <description>Time from randomization to death due to causes other than disease relapse or disease progression</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
    <description>Time to CD3+ &gt; 0.2×10E9/l in peripheral blood (at two consecutive measurements; time to first measurement)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cumulative incidence of grade II-IV and grade III-IV acute graft-versus-host-disease (GVHD)</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cumulative incidence of moderate/severe chronic GVHD</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cumulative incidence of chronic GVHD requiring systemic immunosuppressive treatment</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of GVHD episodes</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cumulative incidence of NCI CTCAE grade 2-5 and grade 3-5 infections</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
    <description>Viral, fungal, and bacterial infections</description>
  </other_outcome>
  <other_outcome>
    <measure>Cumulative incidence of NCI CTCAE grade 3-5 adverse events</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
    <description>Viral, fungal, and bacterial infections</description>
  </other_outcome>
  <other_outcome>
    <measure>FACT-BMT total score (change from screening)</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
    <description>Quality of life: Foundation for the Accreditation of Cellular Therapy - Bone Marrow Transplantation questionnaire (FACT-BMT)</description>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 total score (change from screening)</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
    <description>Quality of life: Short Form 36-item health survey (SF-36)</description>
  </other_outcome>
  <other_outcome>
    <measure>MDASI total score (change from screening)</measure>
    <time_frame>Until 2 years after the HSCT</time_frame>
    <description>Quality of life: MD Anderson Symptom Inventory (MDASI)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">195</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>ATIR101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-cell depleted HSCT from a related, haploidentical donor, followed by IV infusion with ATIR101 at a single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTCy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>T-cell replete HSCT from a related, haploidentical donor, followed by IV infusion of post-transplant cyclophosphamide (PTCy) 50 mg/kg/day at 3 and 4/5 days after the HSCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATIR101</intervention_name>
    <description>ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)</description>
    <arm_group_label>ATIR101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)</description>
    <arm_group_label>PTCy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>T-cell depleted HSCT from a related, haploidentical donor</intervention_name>
    <description>T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a myeloablative conditioning regimen</description>
    <arm_group_label>ATIR101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>T-cell replete HSCT from a related, haploidentical donor</intervention_name>
    <description>T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a myeloablative conditioning regimen</description>
    <arm_group_label>PTCy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any of the following hematologic malignancies:

               -  Acute myeloid leukemia (AML) in first cytomorphological remission (&lt; 5% blasts in
                  the bone marrow) with Disease Risk Index (DRI) intermediate or above, or in
                  second or higher cytomorphological remission

               -  Acute lymphoblastic leukemia (ALL) in first or higher remission (&lt; 5% blasts in
                  the bone marrow)

               -  Myelodysplastic syndrome (MDS): transfusion-dependent (requiring at least one
                  transfusion per month), or intermediate or higher Revised International
                  Prognostic Scoring System (IPSS-R) risk group

          -  Clinical justification of allogeneic stem cell transplantation where a suitable HLA
             matched sibling or unrelated donor is unavailable in a timely manner. An unrelated
             donor search is not required for a patient to be eligible if the clinical situation
             dictates an urgent transplantation. Clinical urgency is defined as 6-8 weeks from
             referral to transplant center or low likelihood of finding a matched unrelated donor

          -  Availability of a related haploidentical donor with ≥ 4/8 but &lt; 7/8, or ≥ 5/10 but &lt;
             9/10 matches at the HLA-A, -B, -C, -DRB1, and/or -DQB1 loci, as determined by high
             resolution human leukocyte antigen (HLA)-typing

          -  Karnofsky Performance Status (KPS) ≥ 70%

          -  Male or female, age ≥ 18 years and ≤ 70 years. Patients aged ≥ 65 years must have a
             Sorror score ≤ 3

          -  Availability of a donor aged ≥ 16 years and ≤ 75 years who is eligible according to
             local requirements and regulations

          -  For females of childbearing potential who are sexually active and males who have
             sexual contact with a female of childbearing potential: willingness to use of reliable
             methods of contraception (oral contraceptives, intrauterine device, hormone implants,
             contraceptive injection or abstinence) during study participation

          -  Given written informed consent (patient and donor)

        Exclusion Criteria:

          -  Availability of a suitable HLA-matched sibling or unrelated donor in a donor search

          -  Prior allogeneic hematopoietic stem cell transplantation

          -  Diffusing capacity for carbon monoxide (hemoglobin corrected DLCO) &lt; 50% predicted

          -  Left ventricular ejection fraction &lt; 45% (evaluated by echocardiogram or MUGA scan)

          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 2.5 × upper
             limit of normal (CTCAE grade 2)

          -  Bilirubin &gt; 1.5 × upper limit of normal (CTCAE grade 2)

          -  Creatinine clearance &lt; 50 ml/min (calculated or measured)

          -  Positive pregnancy test or breastfeeding of patient or donor (women of childbearing
             age only)

          -  Estimated probability of surviving less than 3 months

          -  Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)

          -  Known hypersensitivity to cyclophosphamide or any of its metabolites

          -  Any contraindication for GVHD prophylaxis with mycophenolate mofetil, cyclosporine A,
             or tacrolimus

          -  Known presence of HLA antibodies against the non-shared donor haplotype

          -  Positive human immunodeficiency virus (HIV) test

          -  Positive viral test of the donor for HIV-1, HIV-2, hepatitis B virus (HBV), hepatitis
             C virus (HCV), Treponema pallidum, human T-lymphotropic virus (HTLV) 1 (if tested),
             HTLV-2 (if tested), West Nile virus (WNV; if tested), or Zika virus (if tested)

          -  Any other condition that, in the opinion of the investigator, makes the patient or
             donor ineligible for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Claude Roy, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Center and Cellular Therapy Laboratory, Maisonneuve-Rosemont Hospital (Montreal, Canada)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Mielke, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital (Stockholm, Sweden)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Sandler, MD PhD</last_name>
    <phone>+31 20 3140 250</phone>
    <email>clinicaltrials@kiadis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Wilfried Schroyens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominik Selleslag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Lewalle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johan Maertens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yves Beguin, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Denis Claude Roy, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt, Goethe University</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gesine Bug, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eva Maria Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Götz-Ulrich Grigoleit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina da Universidade de Lisboa</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>João Forjaz de Lacerda, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Barcelona Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Valcarcel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rafael Duarte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servicio de Hematología Hospital, Universitari I politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jose Luis Piñana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bhuvan Kishore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Gilleece, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Amit Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eduardo Olavarria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eleni Tholouli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haploidentical stem cell transplantation</keyword>
  <keyword>Graft-versus-host disease</keyword>
  <keyword>Immune reconstitution</keyword>
  <keyword>Alloreactive T-cells</keyword>
  <keyword>Photodynamic treatment</keyword>
  <keyword>Hematologic malignancy</keyword>
  <keyword>Transplant-related mortality</keyword>
  <keyword>Overall survival</keyword>
  <keyword>GRFS</keyword>
  <keyword>GVHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

